KAPA
No price yet
Announcements
Nothing here yet
Daily updates
- Kairos Pharma reported preliminary Phase 2 mCRPC results showing median PFS of 17.7 months with ENV-105 plus apalutamide versus 2.0 months with apalutamide alone.Oct 7, 2026
- Kairos Pharma reported interim Phase 2 mCRPC data showing median PFS of 17.7 months with ENV-105 plus apalutamide versus 2.0 months with apalutamide alone.Oct 6, 2026
FDA designations
Nothing here yet
News
- Kairos Pharma partners with Bayer to enhance XOFIGO efficacy in metastatic prostate cancerJul 22, 2026
- Kairos Pharma reported breakthrough interim Phase 1 safety data for ENV-105 in EGFR-mutated lung cancerJul 15, 2026
- Kairos Pharma signed a binding agreement to acquire exclusive global rights to CL-273 from Celyn TherapeuticsMar 2, 2026
- Kairos Pharma to present positive safety and efficacy data from Phase 2 prostate cancer trial at ESMO 2025Oct 7, 2025
- Kairos Pharma announces positive interim efficacy analysis of Phase 2 trial of ENV105 in advanced prostate cancer with median progression-free survival over one yearSep 18, 2025